TBPH
$13.92
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
Intraday
Recent News
Assertio (ASRT) Reports Q4 Loss, Beats Revenue Estimates
Assertio (ASRT) delivered earnings and revenue surprises of +39.02% and +185.10%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
How The Theravance Biopharma (TBPH) Story Is Reset Around Respiratory Assets And Cash
The consensus fair value estimate for Theravance Biopharma has shifted from about US$26.71 to roughly US$15.83 per share, a cut of around 40% that resets expectations around what the stock might be worth. Analysts link this move to the CYPRESS outcome, with more bullish voices pointing to Yupelri, residual Trelegy rights, and cash as support, while more cautious views focus on the loss of ampreloxetine as an upside driver and lowered targets in the mid teens. As you read on, you will see how...
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)
Theravance Bio (TBPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)
The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure
Following the wind down of its R&D arm, Theravance will generate revenue from two partnered, commercialised assets.